Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 1037 results for criteria

  1. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA524

  2. The role of families in supporting young adults discharged from children's services:- What is the most effective way of helping families to support young people who have been discharged from children's services (whether or not they meet criteria for adult services)?

    have been discharged from children's services (whether or not they meet criteria for adult services)? Any explanatory notes(if...

    Research recommendation
    Published
    21 March 2016

  3. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    1 August 2013
    View recommendations

    Sections for TA215

  4. Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

    Medical technologies guidance
    Published
    10 January 2019
    View recommendations

    Sections for MTG40

  7. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

    Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.

    Technology appraisal guidance
    Last updated
    24 August 2016
    View recommendations

    Sections for TA391

  8. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA402

  9. The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?

    and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision? Any explanatory notes(if...

    Research recommendation
    Published
    16 December 2021

  10. Subcutaneous efgartigmod for treating generalised myasthenia gravis TS ID 11835

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  12. Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA171

  13. Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

    Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults.

    Technology appraisal guidance
    Published
    18 May 2022
    View recommendations

    Sections for TA789

  14. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA450

  15. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.

    Technology appraisal guidance
    Published
    26 January 2011
    View recommendations

    Sections for TA213